Evidence map›Paper›PMID 36372724›Full record

ArticleJournal of geriatric oncology2023

Referral to and receipt of allogeneic hematopoietic stem cell transplantation in older adults with acute myeloid leukemia.

Dharmini Manogna, Jodi J Lipof, Andrea M Baran, Bassil Said, Michael W Becker, Jason H Mendler, Omar S Aljitawi, Kristen M O'Dwyer, Eric Huselton, Richard Burack and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of geriatric oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Dharmini ManognaDepartment of Hematology and Oncology, Tulane University School of Medicine, New Orleans, LA, USA. Electronic address: dmanogna@tulane.edu.
Jodi J LipofDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: jodi_lipof@urmc.rochester.edu.
Andrea M BaranDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: andrea_baran@urmc.rochester.edu.
Bassil SaidDepartment of Hematology and Oncology, Stony Brook University, Long Island, New York, USA. Electronic address: bassil.said@stonybrookmedicine.edu.
Michael W BeckerDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: michael_becker@urmc.rochester.edu.
Jason H MendlerDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: jason_mendler@urmc.rochester.edu.
Omar S AljitawiDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: omar_aljitawi@urmc.rochester.edu.
Kristen M O'DwyerDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: kristen_odwyer@urmc.rochester.edu.
Eric HuseltonDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: eric_huselton@urmc.rochester.edu.
Richard BurackDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: richard_burack@urmc.rochester.edu.
Margaret BlaneyDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: margaret_blaney@urmc.rochester.edu.
Jane L LiesveldDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: jane_liesveld@urmc.rochester.edu.
Kah Poh LohDivision of Hematology/Oncology, Department of Medicine, James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester, New York, USA. Electronic address: kahpoh_loh@urmc.rochester.edu.
University of Rochester Medical Center · USStony Brook University · USTulane University · US

Funding

A novel mobile health exercise intervention for older patients with myeloid neoplasmsR00CA237744 · NCI · UNIVERSITY OF ROCHESTER · PI LOH, KAH POH · 2021 to 2023
$747k
Epigenetic markers, functional status, and exercise in older adults with myeloid neoplasmsR03AG073985 · NIA · UNIVERSITY OF ROCHESTER · PI LOH, KAH POH · 2022 to 2023
$308k
NCI NIH HHS R00 CA237744NIA NIH HHS R03 AG073985
6 · The paper itself

Abstract

introductionRecent data have shown improved outcomes in selected older adults with acute myeloid leukemia (AML) following allogeneic hematopoietic stem cell transplantation (HSCT). Nonetheless, practice patterns for referring and performing HSCT vary. We aimed to evaluate referral, utilization, and reasons for not referring/proceeding to HSCT in older adults with AML. MATERIALS AND

methodsThis is a single center retrospective analysis of patients aged ≥60 years diagnosed with AML evaluating rates of HSCT referral and utilization. Fisher's exact test was used to compare rates of referral and utilization across age groups and years of diagnosis.

resultsMedian age of the 97 patients was 70 years (range 61-95); 30% (29/97) were referred for HSCT and of these, 69% (20/29) received HSCT. Common documented reasons (can be multiple) for not referring were performance status (n = 21), advanced age (n = 16), patient refusal (n = 15), refractory disease (n = 14), and prohibitive comorbidity (n = 6). Among patients who were referred but did not receive HSCT (n = 9/29), documented reasons for not proceeding with HSCT were refractory disease (n = 5), advanced age (n = 2), and prohibitive comorbidity (n = 2). HSCT referral and utilization rates significantly decreased with age (p < 0.01) but were generally stable over time from 2014 to 2017 (p = 0.40 for referral and p = 0.56 for utilization). DISCUSSION: Despite improvements in supportive care and HSCT techniques, HSCT referral and utilization rates remained low among older adults with AML but stable over time.

Indexed as

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAgedAged, 80 and overComorbidityHumansRetrospective StudiesTransplantation, HomologousAcute myeloid leukemiaAllogeneic hematopoietic stem cell transplantationOlder adults

Identifiers

PMID36372724
PMCPMC9975032
OpenAlexW4308695966

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.